🔗 Share this article

As the United States continues making historic adjustments to its vaccination recommendations, one figure appears in a surprising turn: Tracy Beth Høeg, a US-based sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines during the global health crisis and has focused upon potential deaths after COVID-19 immunization in her recent tenure at the Food and Drug Administration.

Planned Overhauls to Pediatric Vaccine Program

Health officials were set to unveil major revisions to the childhood vaccination calendar earlier this month, aligning the US with Denmark’s vaccine program, according to reports – a substantial departure that would place the US at odds with many the global community with little proof for public health gain. The announcement has been postponed until the next year.

Instead of the top vaccines chief, Dr. Høeg is scheduled to present at the event. She was newly appointed interim head of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the office this year.

A Shift at the FDA

This interim role might represent a tighter collaboration between the pharmaceutical and vaccine divisions as Dr. Høeg and Prasad solidify control at the FDA – and it points to a greater focus upon rolling back already-approved immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing some childhood immunization guidelines in the US in order to be more in line with Denmark, a society with comprehensive healthcare and a number of inhabitants about the population of Wisconsin’s.

In her initial public appearances, she has persisted in emphasizing on vaccines – usually the responsibility of Prasad, head of the FDA’s CBER – rather than pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no obvious track record in pharmaceutical research, oversight or management, which has been customary for previous directors of the biologics center. She has worked at the FDA as a key advisor to the agency head and CBER since March.

“She appears not to have any of the qualifications” for running the CDER, stated Jonathan Howard. “She’s never run a randomized controlled trial. She is not versed in running a large organization. She lacks background in drug approvals.”

Former commissioners of CBER would “grasp regulatory frameworks and the underlying principles of drug development”, said a former acting FDA commissioner. “Objectively, she lacks the kind of background that prior appointees who led the center have had.”

The drug center has an enormous portfolio at the FDA, the former commissioner emphasized.

“Everybody just zeroes in on the novel medication approvals, but the generic drug division authorizes numerous generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and all of those have to be supervised,” Dr. Woodcock said. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to bite you.”

Furthermore, a substantial administrative aspect to the position, which supervises in excess of 5,000 employees. “It is a enormous leadership role, if you perform it correctly,” she concluded.

Agency Reaction and Contentious Policies

Regarding questions about Høeg’s qualifications and whether this assignment signifies more teamwork among FDA leaders on vaccines, a spokesperson said that the “questions are based on flawed presumptions”.

“This background aligns with the duties of her position,” the spokesperson said, noting the time Høeg spent guiding the agency head on “drug safety and oversight research, including computerized risk analysis and shot safety tracking”.

As acting director, Dr. Høeg inherits the agency head's new fast-track approval initiative, a controversial one-day drug-approval program that reportedly concerned her predecessors. “By what process are these drugs being selected for this fast-track system? Who is making the decisions?” Howard asked. “There’s a lot of confidentiality happening at the FDA right now.”

Broadly speaking, he said, “the Food and Drug Administration looks to be trending towards less stringent regulations of pharmaceuticals, aside from immunizations.”

Public History on Vaccines

Regarding vaccines, Høeg has a more documented, if troubling, history, some experts observe. She authored a research paper using unconfirmed volunteer-provided data to estimate the incidence of myocarditis after COVID-19 immunization. She consulted for the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are pose a greater threat than they are.

Included in her “wish list” for the current federal leadership featured altering rules for new vaccines and halting “optional” immunizations, she stated post-election on a online show. At the agency, Høeg has reportedly floated the idea of barring adolescent males from getting Covid vaccines.

“She’s an all-around true believer who begins with her preconceived notions and works backwards to fit the evidence in a extremely deceptive, dishonest fashion,” Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|